Chemical Structure : Amuvatinib
CAS No.: 850879-09-3
Catalog No.: PC-42451Not For Human Use, Lab Use Only.
Amuvatinib (MP-470) is a potent RTK inhibitor that effectively inhibits c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively.
Packing | Price | Stock | Quantity |
---|---|---|---|
5 mg | $88 | In stock | |
10 mg | $138 | In stock | |
25 mg | $218 | In stock | |
50 mg | Get quote | ||
100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Amuvatinib (MP-470) is a potent RTK inhibitor that effectively inhibits c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively.
Amuvatinib (MP-470) also inhibits several mutants of c-Kit and Axl.
Amuvatinib (MP-470) inhibits prostate cancer cell proliferation (IC50=4-8 uM), promotes cell cycle arrest and apoptosis.
Amuvatinib (MP-470) completely inhibites phosphorylation of the HER members (HER1, 2, 3), binding of PI3K regulatory unit p85 to HER3 and downstream Akt activity in combination with Erlotinib.
Amuvatinib (MP-470) exhibits synergistic effect in LNCaP mouse xenograft model.
M.Wt | 447.5096 | |
Formula | C23H21N5O3S | |
Appearance | Solid | |
Storage |
|
|
Solubility |
10 mM in DMSO |
|
Chemical Name/SMILES |
1-Piperazinecarbothioamide, N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro[3,2-d]pyrimidin-4-yl- |
1. Mahadevan D, et al. Oncogene. 2007 Jun 7;26(27):3909-19.
2. Qi W, et al. BMC Cancer. 2009 May 11;9:142.
4. Bearss DJ, et al. US Patent, US/2008/0226747.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright